Coya Therapeutics, Inc. Common Stock (COYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has a cash flow conversion efficiency ratio of -0.127x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.21 Million) by net assets ($48.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Coya Therapeutics, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Coya Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Coya Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Idsud S.A
PA:ALIDS
|
-0.907x |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
-0.016x |
|
Nicola Mining Inc
V:NIM
|
0.542x |
|
Maxigen Biotech Inc
TW:1783
|
0.049x |
|
Alterity Therapeutics Ltd
AU:ATH
|
-0.196x |
|
Riber S.A
PA:ALRIB
|
-0.100x |
|
Magnate Technology Co Ltd
TWO:4541
|
0.115x |
|
FastPartner AB Series D
ST:FPAR-D
|
0.009x |
Annual Cash Flow Conversion Efficiency for Coya Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Coya Therapeutics, Inc. Common Stock from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see COYA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $43.03 Million | $-10.74 Million | -0.250x | +3.99% |
| 2024-12-31 | $39.58 Million | $-10.29 Million | -0.260x | +17.20% |
| 2023-12-31 | $35.64 Million | $-11.19 Million | -0.314x | -136.40% |
| 2022-12-31 | $-8.39 Million | $-7.24 Million | 0.862x | +180.51% |
| 2021-12-31 | $3.64 Million | $-3.90 Million | -1.071x | -2172.96% |
| 2020-12-31 | $8.30 Million | $-391.27K | -0.047x | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more